妊娠期间歇性预防治疗对疟原虫抗药性多态性的反向选择
研究基于2010–2013年贝宁、加蓬、肯尼亚和莫桑比克的2项随机临床试验,共分析914株恶性疟原虫分离株,比较HIV未感染孕妇接受IPTp-甲氟喹(MQ)与IPTp-磺胺多辛-乙胺嘧啶(SP)、以及HIV感染孕妇接受IPTp-MQ与安慰剂的抗药性标志物选择。结果显示HIV未感染孕妇中IPTp-MQ组pfmdr1 86Y多态性流行率低于IPTp-SP组,且IPTp-MQ组分娩时低于入组时;HIV感染孕妇中未观察到IPTp-MQ对抗药性标志物的影响,抗药性标志物携带与妊娠结局无关。
要点
- IPTp-MQ对HIV未感染孕妇选择野生型pfmdr1 N86多态性,显示强选择压力。
- IPTp-MQ组pfmdr1 86Y流行率低于IPTp-SP组,且分娩时低于入组时。
- HIV感染孕妇中未观察到IPTp-MQ对抗药性标志物的影响。
核心结论
- IPTp-MQ选择野生型pfmdr1 N86多态性,提示IPTp可施加强选择压力并可能利用负交叉耐药优化药物选择。
- 抗药性标志物携带与妊娠结局无关。
研究设计与样本
- 基于2项随机临床试验,2010–2013年在贝宁、加蓬、肯尼亚和莫桑比克开展。
- 共筛查914株恶性疟原虫分离株的pfmdr1拷贝数变异及pfcrt、pfmdr1、pfdhfr、pfdhps抗药性标志物。
- 试验比较HIV未感染孕妇IPTp-MQ与IPTp-SP、HIV感染孕妇IPTp-MQ与安慰剂的疗效。
主要发现
- HIV未感染孕妇中,pfcrt突变体、pfdhfr/pfdhps五重突变体及pfmdr1拷贝数在IPTp-SP组与IPTp-MQ组间相似。
- HIV未感染孕妇中,pfmdr1 86Y多态性流行率IPTp-MQ组低于IPTp-SP组,且IPTp-MQ组分娩时低于入组时。
- HIV感染孕妇中未观察到IPTp-MQ对抗药性标志物的影响。
- 抗药性标志物携带与妊娠结局无关。
临床怎么用
- IPTp-MQ可反向选择野生型pfmdr1 N86,提示在临床治疗和IPTp药物选择中可利用负交叉耐药。
- HIV感染孕妇中IPTp-MQ对抗药性标志物未见选择效应,需考虑人群差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Innovative approaches are needed to limit antimalarial resistance evolution. Understanding the role of intermittent preventive treatment in pregnancy (IPTp) on the selection for resistance and the impact such selection has on pregnancy outcomes can guide future interventions. METHODS: Plasmodium falciparum isolates (n = 914) from 2 randomized clinical trials were screened for pfmdr1 copy number variation and pfcrt, pfmdr1, pfdhfr, and pfdhps resistance markers. The trials were conducted between 2010 and 2013 in Benin, Gabon, Kenya, and Mozambique to establish the efficacy of IPTp-mefloquine (MQ) compared with IPTp-sulphadoxine-pyrimethamine (SP) in human immunodeficiency virus (HIV)-uninfected and to IPTp-placebo in HIV-infected women. RESULTS: In HIV-uninfected women, the prevalence of pfcrt mutants, pfdhfr/pfdhps quintuple mutants, and pfmdr1 copy number was similar between women receiving IPT-SP and IPTp-MQ. However, prevalence of pfmdr1 polymorphism 86Y was lower in the IPTp-MQ group than in the IPTp-SP group, and within the IPTp-MQ group it was lower at delivery compared with recruitment. No effect of IPTp-MQ on resistance markers was observed among HIV-infected women. The carriage of resistance markers was not associated with pregnancy outcomes. CONCLUSIONS: Selection of wild-type pfmdr1 polymorphism N86 by IPTp-MQ highlights the strong selective pressure IPTp can exert and the opportunity for using negative cross-resistance in drug choice for clinical treatment and IPTp.
引用
- Huijben S, Macete E, Mombo-Ngoma G, et al. Counter-Selection of Antimalarial Resistance Polymorphisms by Intermittent Preventive Treatment in Pregnancy. J Infect Dis. 2020. PMID: 31677349. doi:10.1093/infdis/jiz451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。